Multiple sclerosis and related disorders · 2025
Decoding disease burden in multiple sclerosis: The role of IL-10 as biomarker of neuroinflammation and neurodegeneration.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khedr Eman M, El-Deen Hussein Bahey, El-Mokhtar Mohamed A, Mahmoud Doaa M
Аннотация
BACKGROUND: Multiple sclerosis (MS) is a chronic neuroinflammatory disease with heterogeneous clinical presentations and progression rates that pose challenges to its management. Identifying prognostic biomarkers is crucial for individualized treatment approaches. Interleukin-10 (IL-10) has emerged as a key anti-inflammatory cytokine with neuroprotective effects, while Chitinase-3-like protein 1 (CHI3L1) reflects the pathogenic glial activation and neurodegeneration.
OBJECTIVE: This study aimed to assess baseline serum IL-10 and CHI3L1 levels as biomarkers of disease burden and their correlation with clinical, cognitive, and quality-of-life (QoL) parameters in disease-modifying therapy (DMT)-naïve MS patients.
METHODS: A cross-sectional, case-control study was conducted on 115 DMT-naïve MS patients and 15 healthy controls. Only 73 RRMS and 29 CIS confirmed MS participated in the study analysis. Serum IL-10 and CHI3L1 levels were measured using sandwich ELISA kits and were correlated with various demographic, clinical, motor, cognitive, and quality of life (QOL) parameters.
RESULTS: Serum levels of IL-10 and CHI3L1 were significantly higher among MS patients compared to the healthy controls (P = 0.0001 for each one) and were negatively correlated with each other (r =-0.529 and P < 0.001). Second finding IL-10 levels negatively correlated with duration of disease (r = -0.389, P < 0.001), total number of relapse (r = -0.445, P < 0.001), motor disability (EDSS), Timed 25-Foot walk test (25-FWT), and depression scores (r = -0.398, P = 0.003, r = -0.340, P = 0.002 and r = -0.288, P = 0.008 respectively). It's positively correlated with most domains of QoL. CHI3L1 correlated positively with the total number of relapses (r = 0.253, P = 0.021), and EDSS (r = 0.346, P = 0.001), while negatively correlated with vitality, social, physical function, and general health domains of QoL (P = 0.009, 0.03, 0.001, and 0.013, respectively) CONCLUSION: IL-10 serves as a potential biomarker for disease burden in MS, with protective effects on QoL, highlighting its role in the early identification of favorable disease profiles and personalized disease management.
OBJECTIVE: This study aimed to assess baseline serum IL-10 and CHI3L1 levels as biomarkers of disease burden and their correlation with clinical, cognitive, and quality-of-life (QoL) parameters in disease-modifying therapy (DMT)-naïve MS patients.
METHODS: A cross-sectional, case-control study was conducted on 115 DMT-naïve MS patients and 15 healthy controls. Only 73 RRMS and 29 CIS confirmed MS participated in the study analysis. Serum IL-10 and CHI3L1 levels were measured using sandwich ELISA kits and were correlated with various demographic, clinical, motor, cognitive, and quality of life (QOL) parameters.
RESULTS: Serum levels of IL-10 and CHI3L1 were significantly higher among MS patients compared to the healthy controls (P = 0.0001 for each one) and were negatively correlated with each other (r =-0.529 and P < 0.001). Second finding IL-10 levels negatively correlated with duration of disease (r = -0.389, P < 0.001), total number of relapse (r = -0.445, P < 0.001), motor disability (EDSS), Timed 25-Foot walk test (25-FWT), and depression scores (r = -0.398, P = 0.003, r = -0.340, P = 0.002 and r = -0.288, P = 0.008 respectively). It's positively correlated with most domains of QoL. CHI3L1 correlated positively with the total number of relapses (r = 0.253, P = 0.021), and EDSS (r = 0.346, P = 0.001), while negatively correlated with vitality, social, physical function, and general health domains of QoL (P = 0.009, 0.03, 0.001, and 0.013, respectively) CONCLUSION: IL-10 serves as a potential biomarker for disease burden in MS, with protective effects on QoL, highlighting its role in the early identification of favorable disease profiles and personalized disease management.